Altimmune, Inc. (NYSE:ALT) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $10.00 for the company and are anticipating that the company will post ($2.80) EPS for the current quarter, according to Zacks. Zacks has also given Altimmune an industry rank of 84 out of 257 based on the ratings given to its competitors.

ALT stock traded up $0.32 during trading on Wednesday, reaching $3.36. The stock had a trading volume of 47,500 shares, compared to its average volume of 302,968. Altimmune has a 1-year low of $2.85 and a 1-year high of $66.00.

About Altimmune

Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.

See Also: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Altimmune (ALT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with's FREE daily email newsletter.